Astria Therapeutics (ATXS) Jefferies Global Healthcare Conference 2025 summary

Strategic focus and pipeline overview

• Focused on developing first-choice therapies for allergic and immunologic diseases, prioritizing efficacy, safety, and low treatment burden.

• Lead asset navenibart, a plasma kallikrein inhibitor, is in phase III for hereditary angioedema (HAE), showing >90% attack rate reduction in proof-of-concept trials.

• Phase III trial includes both three-month and six-month dosing regimens, aiming to offer flexibility and maximize market share.

• Second program, STAR-0310, targets the OX40 receptor for atopic dermatitis, with phase I data expected later this year.

Clinical development and trial design

• Phase III navenibart trial initiated in February, enrolling in the US, Canada, and expanding globally; top-line data expected early 2027.

• Both dosing regimens (Q3M and Q6M) are tested in a single trial, offering operational cost savings and broader patient options.

• Three navenibart arms and a placebo arm, with each compared individually to placebo.

• Adolescents included without a placebo arm, based on regulatory feedback, to support label inclusion.

Efficacy, safety, and market positioning

• Navenibart expected to achieve 80%-90% attack rate reduction in phase III, with attack-free rate as a key secondary endpoint.

• Long-term extension trial (ALPHA-SOLAR) to provide additional safety and efficacy data, with results expected mid-year.

• Market research indicates strong physician and patient interest in both dosing regimens, with potential for navenibart to become market leader.

• Navenibart's mechanism and modality align with current market leader, but offers less frequent dosing and no injection site pain.